DWAS - ETF AI Analysis

Top Page

Invesco DWA SmallCap Momentum ETF (DWAS)

Rating:62Neutral

Price Target:―

DWAS has a solid overall rating, suggesting it offers a reasonably attractive way to invest in small-cap stocks with strong momentum. The fund is helped by holdings like Sezzle and Frequency Electronics, which show strong financial performance, positive earnings sentiment, and supportive technical trends. However, several early-stage biotech names such as Kodiak Sciences and Terns Pharmaceuticals face no revenue and ongoing losses, adding risk and slightly weighing on the fund’s overall appeal, with notable exposure to high-risk biotech being a key risk factor.

Positive Factors

Strong Recent Performance

The ETF has shown solid gains over the past three and twelve months, indicating positive recent momentum in its strategy.

Momentum-Focused Small-Cap Strategy

Many of the top holdings have delivered strong year-to-date gains, reflecting the fund’s focus on small companies with improving stock trends.

Meaningful Asset Base

With several hundred million dollars in assets, the fund is large enough to suggest steady investor interest and operational stability.

Negative Factors

High Expense Ratio

The fund’s fees are relatively high for an ETF, which can eat into long-term returns compared with lower-cost options.

Heavy Health Care Concentration

A large portion of the portfolio is in health care stocks, increasing the risk that sector-specific setbacks could hurt overall performance.

U.S.-Only Exposure

Almost all holdings are in U.S. companies, offering little geographic diversification if the U.S. market faces a downturn.

DWAS vs. SPDR S&P 500 ETF (SPY)

AUM389.61M

RegionNorth America

Expense Ratio0.60%

Beta1.22

IssuerInvesco

Inception DateJul 19, 2012

Dividend Yield0.14%

Asset ClassEquity

Index TrackedDorsey Wright SmallCap Tech Leaders Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume17,297

30 Day Avg. Volume83,457

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

126.81

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering200

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

DWAS Summary

The Invesco DWA SmallCap Momentum ETF (DWAS) tracks the Dorsey Wright SmallCap Technical Leaders Index, which focuses on smaller U.S. companies whose stock prices have been rising strongly. It holds a wide mix of sectors, with a big tilt toward health care and industrials, and includes lesser-known names like Bel Fuse and Planet Labs. Someone might invest in DWAS if they want growth potential from small, fast-moving companies and diversification away from large, well-known stocks. A key risk is that small-cap momentum stocks can be very volatile and may fall quickly when market conditions change.

How much will it cost me?The Invesco DWA SmallCap Momentum ETF (DWAS) has an expense ratio of 0.6%, meaning you’ll pay $6 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on small-cap stocks with strong momentum, which requires more research and management compared to passively managed ETFs. It’s designed for investors seeking growth opportunities in dynamic, smaller companies.

What would affect this ETF?The DWAS ETF, focused on U.S. small-cap stocks with strong momentum, could benefit from economic growth and innovation in sectors like Health Care and Technology, which make up a significant portion of its holdings. However, it may face challenges during periods of economic uncertainty or rising interest rates, which can negatively impact small-cap companies and momentum-driven strategies. Regulatory changes or sector-specific headwinds could also influence the performance of its top holdings.

DWAS Top 10 Holdings

DWAS is leaning hard into U.S. small-cap health care, with a supporting cast from industrials and niche tech, so a handful of volatile names are steering the ship. Rising stars like Planet Labs, Bel Fuse, and Frequency Electronics have been giving the fund a lift, helped by steady contributions from Graham and Nuvalent. On the flip side, Terns Pharmaceuticals has been a weak link, and Sezzle has recently lost some steam. With so many early-stage and momentum-driven stories, performance is likely to stay lively rather than quiet and predictable.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
BELFB	Bel Fuse Inc	1.95%	$7.61M	$2.91B	182.85%	73 Outperform
TPC	Tutor Perini	1.67%	$6.53M	$4.36B	249.26%	65 Neutral
TERN	Terns Pharmaceuticals	1.45%	$5.65M	$4.02B	830.79%	45 Neutral
PL	Planet Labs PBC	1.43%	$5.57M	$7.47B	269.97%	57 Neutral
GHM	Graham	1.41%	$5.50M	$934.54M	125.01%	69 Neutral
SEZL	Sezzle Inc.	1.38%	$5.41M	$2.19B	12.99%	80 Outperform
CELC	Celcuity	1.30%	$5.10M	$4.84B	711.41%	44 Neutral
NUVL	Nuvalent	1.27%	$4.98M	$7.33B	29.37%	43 Neutral
AMRX	Amneal Pharmaceuticals	1.17%	$4.58M	$4.66B	91.72%	58 Neutral
KOD	Kodiak Sciences	1.16%	$4.52M	$1.35B	319.58%	35 Underperform

DWAS Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price―

Price Trends

50DMA

99.93

Positive

100DMA

96.63

Positive

200DMA

90.67

Positive

Market Momentum

MACD

0.38

Positive

RSI

48.60

Neutral

STOCH

50.89

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For DWAS, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 101.63, equal to the 50-day MA of 99.93, and equal to the 200-day MA of 90.67, indicating a neutral trend. The MACD of 0.38 indicates Positive momentum. The RSI at 48.60 is Neutral, neither overbought nor oversold. The STOCH value of 50.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DWAS.

DWAS Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
DWAS	―	―	$389.61M	0.60%	―
OUSM	―	―	$955.93M	0.48%	―
GSSC	―	―	$885.69M	0.20%	―
JHSC	―	―	$696.37M	0.42%	―
SMDV	―	―	$674.13M	0.40%	―
BBSC	―	―	$662.07M	0.09%	―

Performance Comparison

DWAS

Invesco DWA SmallCap Momentum ETF

100.36

7.49

8.07%

OUSM

OShares U.S. Small-Cap Quality Dividend ETF

―

GSSC

Goldman Sachs Activebeta U.S. Small Cap Equity ETF

―

JHSC

John Hancock Multifactor Small Cap ETF

―

SMDV

ProShares Russell 2000 Dividend Growers ETF

―

BBSC

JPMorgan BetaBuilders U.S. Small Cap Equity ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents